

Edgar Filing: FOUNTAIN PHARMACEUTICALS INC - Form NT 10-Q

FOUNTAIN PHARMACEUTICALS INC
Form NT 10-Q
May 16, 2002

=====

U.S. SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 12b-25

Notification of Late Filing

Form 10-K Form 11-K Form 20-F Form 10-QSB Form N-SAR

For Quarter Ended: March 31, 2002

Nothing in this Form shall be construed to imply that the Commission has verified any information contained herein.

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

N/A

PART I - REGISTRANT INFORMATION

Fountain Pharmaceuticals, Inc.

(Exact Name of Registrant as Specified in Charter)

505 S. Westland Avenue, Suite D
Tampa, FL 33606

(Address of Principal Executive Office)

=====

PART II - RULES 12B-25 (B) AND (C)

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

(a) The reasons described in reasonable detail in Part III of this

Edgar Filing: FOUNTAIN PHARMACEUTICALS INC - Form NT 10-Q

form could not be eliminated without unreasonable effort or expense;

- [X] (b) The subject annual report or semi-annual report/portion thereof will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report/portion thereof will be filed on or before the fifth calendar day following the prescribed due date; and
- (c) The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

PART III - NARRATIVE

State below in reasonable detail the reasons why the Form 10-KSB, 11-K, 20-F, 10-QSB or N-SAR or portion thereof could not be filed within the prescribed time:

The Company's limited resources were consumed by management's efforts to make an acquisition, the closing of which has temporarily been postponed. Due to this reason, the Company was unable to complete this filing on a timely basis without unreasonable effort and expense.

PART IV - OTHER INFORMATION

- (1) Name and telephone number of person to contact in regard to this notification
- Joel C. Schneider, Esq. (516) 228-8181
- (2) Have all other periodic reports required (under Section 13 or 15(d) of the Securities and Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940) during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) been filed? If answer no, identify report(s).

[X] YES [] NO

- (3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statement to be included in the subject report or portion thereof?

[X] YES [] NO

If so, attach an explanation of the anticipated change, both narratively and quantitatively, and; if appropriate, state the reasons why a reasonable estimate of the results can not be made.

A qualitative and quantitative statement cannot be provided at this time, for reasons set forth in Part III above.

Fountain Pharmaceuticals, Inc. has caused this notification to be

Edgar Filing: FOUNTAIN PHARMACEUTICALS INC - Form NT 10-Q

signed on its behalf by the undersigned thereunto duly authorized.

Dated: May 15, 2002

Fountain Pharmaceuticals, Inc.

By: /s/ Brendon K. Rennert

Brendon K. Rennert, President

ATTENTION

Intentional misstatements or omissions of act constitute
Federal Criminal Violations (See 18 U.S.C. 1001).
